Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Martin Glas, Theophilos Tzaridis et al.|The Lancet|2019Cited by 581
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O<sup>6</sup>-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS TrialUlrich Herrlinger, Martin Glas, Niklas Schäfer et al.|Journal of Clinical Oncology|2016Cited by 197
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07)Dagmar Beier, Peter Hau, Martin Proescholdt et al.|Neuro-Oncology|2017Cited by 90
ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trialUlrich Herrlinger, Martin Glas, Theophilos Tzaridis et al.|Neuro-Oncology|2017Cited by 22